Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2017-07-24 17:30:17
Reporting Period:
Filing Date:
Accepted Time:
2017-07-24 17:30:17
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1457612 Genocea Biosciences Inc. GNCA Biological Products, (No Disgnostic Substances) (2836) 510596811
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604689 Jonathan Poole C/o Genocea Biosciences, Inc.
100 Acorn Park Drive, 5Th Floor
Cambridge MA 02140
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-07-24 45,000 $3.09 84,247 No 4 M Direct
Common Stock Disposition 2017-07-24 45,000 $6.00 39,247 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-07-24 45,000 $0.00 45,000 $3.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
90,000 2026-02-01 No 4 M Direct
  1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 10, 2017 by the reporting person.
  2. These shares were sold in multiple transactions at a price of $6.00. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold.
  3. The option was granted on 2/2/2016 and vests in 48 equal monthly installments beginning on the first monthly anniversary of the grant date.